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CHAPTER 1 
ABSTRACT 
 
Brain-derived neurotrophic factor (BDNF) and its high affinity receptor tyrosine kinase 
receptor B (TrkB) are involved in maintaining neuronal survival, differentiation, and 
synaptic plasticity. In our previous study, in silico screening to identify compounds 
targeting the BDNF binding domain of TrkB led to a hypothesis that the candidate 
compounds activate TrkB signaling. To test this hypothesis in the present study, we first 
examined the selected compounds for their proliferative effects in TrkB-expressing 
SH-SY5Y cells. The two positive compounds, 48 and 56, were then assessed for their 
ability to induce TrkB phosphorylation in vitro and in vivo. The elevated 
phosphorylation of TrkB by the compounds was blocked by the Trk inhibitor, K252a. 
Because dysfunction of BDNF-TrkB signaling is associated with the pathogenesis of 
depression, we conducted a forced swim test to confirm the efficacy of the compounds 
in a mouse model of depression. We found that compound 48 significantly reduced 
mouse immobility time compared with that following a vehicle injection, suggesting an 
antidepressant-like effect of the compound in vivo. Thus, our present study 
demonstrated that compound 48, selected through in silico screening, is a novel 
activator of TrkB signaling and a potential antidepressant agent. 
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CHAPTER 2 
INTRODUCTION 
 
Brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family, which 
contains nerve growth factor, neurotrophin-3, and neurotrophin-4, is a specific ligand 
for tropomyosin-related kinase receptor B (TrkB). The binding of BDNF to TrkB 
triggers the dimerization of the receptor via conformational changes and the 
autophosphorylation of tyrosine residues in the intracellular domain of the receptor, 
leading to activation of the downstream signaling pathways involving extracellular 
signal-regulated kinase (ERK), phosphoinositide 3-kinase, and phospholipase C-gamma 
(Numakawa et al, 2013). BDNF-TrkB signaling contributes to neuronal survival, 
differentiation, and synaptic plasticity in the central nervous system. Accumulating 
evidence suggests that dysregulation of the BDNF-TrkB signaling pathway is associated 
with several neurodegenerative diseases, including Huntington disease (Ferrer et al, 
2000), Alzheimer disease (Durany et al, 2000), amyotrophic lateral sclerosis (Ekestern, 
2004), and depression (Lindholm and Castrén, 2014; Hashimoto et al, 2004; Nestler et 
al, 2002). Among these disorders, a decreased level of BDNF expression is reportedly 
associated with the pathogenesis of depression (Karege et al, 2005; Shimizu et al, 2003). 
BDNF and TrkB are considered attractive therapeutic targets because of their important 
role in the efficacy of antidepressants (Shirayama et al, 2002). However, obtaining 
pharmacological agents that activate BDNF-TrkB signaling in brain will require 
developing new compounds that can penetrate the blood-brain barrier. We previously 
conducted in silico screening to find low molecular weight compounds interacting with 
the BDNF binding domain of TrkB (Nakamura et al, 2014). Among the candidate 
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chemicals, we identified two compounds that function as TrkB antagonists. In the 
present study, we hypothesize that other compounds selected by the screening contained 
potential TrkB activators or agonists. To test this hypothesis, we assessed these other 
compounds for their ability to induce activation of TrkB signaling in vitro and in vivo. 
TrkB activation has been reported in rat and mouse brain tissues after antidepressant 
treatment (Nibuya et al, 1995; Saarelainen et al, 2003). Therefore, we also conducted 
the forced swim test (FST) using mice to assess the pharmacological effects of the 
compounds against depression-like behavior. 
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CHAPTER 3 
MATERIALS AND METHODS 
 
3-1. Reagents, cells, and mice 
Small molecules identified during in silico screening were purchased from Namiki Shoji 
Co. Ltd. (Tokyo, Japan). Human neuroblastoma-derived SH-SY5Y/TrkB cells were a 
gift from Dr. Angelika Eggert (University Children’s Hospital Essen, Essen, Germany) 
and grown in RPMI 1640 medium (Sigma, Tokyo, Japan). A mouse neuroblastoma cell 
line, Neuro2a, was maintained in Dulbecco’s modified Eagle’s medium (Sigma)  
 
3-2. Cell growth/survival assays  
SH-SY5Y/TrkB and Neuro2a cells were seeded with media containing 2% and 1% FBS, 
respectively. After overnight culture, the cells were treated with DMSO, the selected 
compounds (0.06–2.0 µM or 0.1–3.0 µM), or BDNF (1–50 ng/mL, Wako, Osaka, 
Japan), as indicated. The plate was incubated and monitored for 9 days in an IncuCyte 
live-cell imaging system (Essen Bioscience, Michigan, USA) according to the 
manufacturer’s instructions. SH-SY5Y/TrkB cells were pre-treated with the Trk 
receptor inhibitor K252a (Sigma) (200 nM) for 30 min after pre-culture in serum-free 
medium for 2.5 h. Cells were then treated with DMSO, BDNF (1 ng/mL), or 
compounds 48 or 56 (0.3 µM) for 1 h.  
For the TrkB inhibition assay, SH-SY5Y/TrkB cells were seeded with medium 
containing 2% FBS and allowed to attach overnight. Cells were then treated with BDNF 
(5 ng/mL) or compound (1 µM) in the presence of K252a (100 nM). Detailed methods 
are provided in supplemental information. 
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3-3. Immunoblotting 
Cells were pre-cultured in serum-free medium for 2.5 h and then treated with DMSO, 
compounds, or BDNF for the indicated times. The total cell lysates were subjected to 
immunoblotting analyses using the following primary antibodies: anti-TrkB antibody 
(1:1000 dilution), anti-TrkB antibody (1:1000), anti-AKT antibody (1:1 000), anti-ERK 
antibody (1:1 000), anti-β tubulin (1:10 000), anti-phospho-TrkB (1:1 000), 
anti-phospho-AKT (1:1 000), anti-phospho-ERK (1:1 000). 
 
3-4. Treatment of mice with compounds 
Eight-week-old male C57BL/6J mice (CREA Japan Inc., Tokyo, Japan) were 
maintained in a temperature-controlled environment for 1 week prior to the start of 
experiments. All animal experiments were performed in compliance with the 
regulations for animal experiments at the Chiba Cancer Center Research Institute after 
obtaining approval by the Animal Ethics Committee of Chiba Cancer Center. The mice 
were intraperitoneally administered DMSO or the compounds (3 or 15 mg/kg body 
weight). After 3 h, the mice were killed, and cerebral cortical and hippocampal samples 
were collected. Tissue lysates were analyzed by immunoblotting with antibodies against 
phospho- (p)TrkB, TrkB, pAKT, AKT, pERK and ERK. The remaining half of the 
tissue was immediately fixed in 4% paraformaldehyde and embedded in OCT 
compound (Sakura, Tokyo, Japan). Frozen sections were cut using a cryostat, and the 
sections were subjected to immunohistochemistry assays using the anti-pTrkB antibody 
visualized with Alexa 488-conjugated secondary antibody (Thermo Fisher Scientific, 
Waltham, MA, USA). Images were captured using a confocal microscope (Leica), and 
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the signal intensities were quantified in nine randomly selected fields on three slides 
using WinROOF software (version 7.0, Mitani Corp., Fukui, Japan). 
 
3-5. Forced swim test 
Male C57BL/6J mice were intraperitoneal injected with DMSO or compounds (3 
mg/kg) for 21 days and then subjected to a forced swim test. They were then placed in a 
clear glass cylinder with a diameter of 20 cm and height of 30 cm filled with clear water 
of approximately 25°C. Their mobility was recorded for 10 min, and the time spent 
immobile was analyzed for the last 4 min of the test after a 3 min pre-swim as well as 
for the entire 10 min without a pre-swim.  
 
3-6. Statistical analysis 
One-way analysis of variance followed by Dunnett’s test was used for multiple group 
comparisons in the cell proliferation assay. Student’s t tests were performed for analysis 
of the differences between two groups in the immunohistochemistry and FST assays. P 
values less than 0.05 were considered statistically significant. All values are expressed 
as the means ± S.E.  
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CHAPTER 4 
RESULTS 
 
4-1. Identification of chemical compounds promoting cell growth by activating the 
TrkB pathway 
Our previous study identified two compounds (out of three million) that induce cell 
death in neuroblastoma cells and are novel candidate antagonists of TrkB (Nakamura et 
al, 2014). In that study, we also conducted in silico screening to identify compounds 
with the potential of interacting with the BDNF binding domain of TrkB. We 
hypothesized that molecules positive for TrkB interactions may act as TrkB agonists. 
Therefore, in the present study, we first investigated whether 11 compounds selected by 
the in silico screening assay in that previous study (Nakamura et al, 2014) enhanced cell 
proliferation in TrkB-expressing cells. Human neuroblastoma SH-SY5Y cells stably 
expressing TrkB were treated with 10 µM of the compounds and subjected to a cell 
proliferation assay. The number of cells was counted 5 days after the treatment 
(Supplementary Figure S1). Based on the results, we selected the commercially 
available compounds 48 and 56 for further evaluation (Supplementary Figure S2). To 
confirm their ability to promote cell growth in TrkB-expressing cells, we performed an 
in vitro cell growth assay in SH-SY5Y/TrkB cells cultured with a medium containing a 
low percentage of FBS (2%). As expected, the treatment with BDNF markedly 
enhanced cell proliferation compared with the DMSO treatment, in which no viable 
cells were detected 9 days after the treatment (Figure 1a). Compound 48 at 
concentrations above 0.2 µM and compound 56 at 0.6 and 2 µM significantly enhanced 
cell proliferation (Figure 1a). We also conducted in vitro cell growth assays using 
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mouse neuroblastoma Neuro2a cells, which endogenously express TrkB. The treatment 
of BDNF at concentrations above 10 ng/mL tended to enhance the growth of Neuro2a 
cells comparable to that in SH-SY5Y/TrkB cells, although no statistically significant 
difference was found between DMSO and 50 ng/mL of BDNF. Treatment with 
compound 48 also showed a tendency to restore cell growth to a level similar to that 
produced by BDNF (Figure 1b). However, the proliferative effect of compound 56 was 
marginal in Neuro2a cells. 
We next performed western blot analysis to investigate the activation of TrkB and its 
downstream signaling cascades after treatment with the compounds. In SH-SY5Y/TrkB 
cells, TrkB and its downstream molecules AKT and ERK were phosphorylated by 
BDNF treatment (Figure 1c and d). In compound-treated cells at a concentration of 0.3 
µM, TrkB phosphorylation was gradually increased and peaked approximately 30 min 
after treatment, whereas phosphorylation of AKT and ERK was minimal compared with 
that following BDNF treatment (Figure 1c). In concentration-response experiments, the 
compounds induced TrkB phosphorylation 10 min after treatment, with the highest 
phosphorylation of TrkB at 0.1 µM of the compounds (Figure 1d). ERK 
phosphorylation was also elevated by treatment with the compounds in a 
concentration-dependent manner (Figure 1d). We also performed western blot analysis 
to examine the phosphorylation of TrkB by compound 48 in Neuro2a cells. Compared 
with that following DMSO treatment, TrkB and AKT phosphorylation were slightly 
increased after compound 48 treatment in a time-dependent manner, whereas ERK 
phosphorylation was markedly increased at 30 min, with the increase lasting until 60 
min after treatment. (Figure 1e). These results suggest that compounds 48 and 56 
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enhance phosphorylation of TrkB and its downstream molecules in TrkB-expressing 
cells. 
 
4-2. Proliferative effects of compounds 48 and 56 require the activation of TrkB  
The Trk tyrosine kinase inhibitor K252a was used to confirm the involvement of TrkB 
activity in the compound 48- and 56-dependent cell proliferation. SH-SY5Y/TrkB cells 
pretreated with K252a were exposed to 0.3 µM of compound 48 or 56 and subjected to 
western blot analysis for TrkB activation. As shown in Figure 2a, phosphorylation of 
TrkB induced by BDNF treatment was completely blocked by K252a treatment. Similar 
reductions in TrkB phosphorylation were observed in compound 48- and 56-treated 
cells, suggesting that these compounds induce TrkB phosphorylation in a manner 
similar to that induced by BDNF. Indeed, the cell growth restored by treating cells 
maintained in a medium having a low percentage of FBS with the compounds was 
completely inhibited by the same co-treatment with K252a that significantly suppressed 
the BDNF-induced cell growth (Figure 2b and c). However, treatment with compounds 
48 and 56 failed to rescue the cell growth of SH-SY5Y/TrkA cells (Supplementary 
Figure S3), suggesting that compounds 48 and 56 function to upregulate cell 
proliferation in a TrkB-dependent manner.  
 
4-3. Compounds 48 and 56 induce TrkB phosphorylation in vivo 
To investigate whether compounds 48 and 56 activate endogenous TrkB in vivo, we 
injected C57BL/6J mice intraperitoneally with 3 mg/kg body weight of the compounds. 
Three hours after the injection, the whole brain was collected and tissue lysates were 
prepared. Western blot analysis showed that TrkB phosphorylation was slightly elevated 
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by treatment with compounds 48 and 56 (Supplementary Figure S4). Because the 
phosphorylation of AKT and ERK showed a tendency to increase, we injected the mice 
with compound 48 at a higher dose (15 mg/kg body weight). No phosphorylation of 
TrkB, AKT, and ERK was detected in the tissue lysates collected from the cerebral 
cortex and hippocampus of mice injected with DMSO or negative control compound 37 
(Figure 3a). By contrast, the compound 48-treated cerebral cortex and hippocampus 
showed high levels of phosphorylation for TrkB, AKT, and ERK. 
Immunohistochemistry assays using the antibody against phosphorylated TrkB also 
revealed increased elevated phosphorylation of TrkB in the hippocampus of compound 
48-treated mice (Figure 3b and c) compared with that in negative controls. These results 
indicate that the intraperitoneally administered compound 48 crosses the blood-brain 
barrier and stimulates the TrkB signaling pathway in vivo. 
 
4-4. Compound 48 produces antidepressant-like effects in mice 
Because previous reports have suggested that the impaired function of the BDNF-TrkB 
signaling pathway is related to depressive behavior (Groves, 2007; Nibuya et al, 1995), 
we next conducted a forced swim test (FST), which is generally used to screen potential 
antidepressants. Male C57BL/6J mice were intraperitoneally administered compound 48 
at a dose of 3 mg/kg body weight per day for 21 days. Three hours after the last 
administration, the FST was conducted and the time spent immobile was recorded. The 
immobility time during the last 4 min of the test after a 3-min pre-swim was 
significantly decreased in the mice injected with compound 48 compared with those 
injected with DMSO (Figure 4a, p = 0.02). The immobility time for the total 10 min of 
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the FST without pre-swim was also significantly lower in mice injected with compound 
48 compared with that in control (Figure 4b, p = 0.016). 
Compound 48 treatment for 21 days did not affect body weight gain (Figure 4c). 
Furthermore, acute in vivo toxicity testing of compound 48 in ICR mice showed no 
adverse effects (data not shown) or body weight changes (Supplementary Figure S5). 
These data suggest that compound 48 has an antidepressant-like action with limited 
toxicity in mice.  
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CHAPTER 5 
DISCUSSION 
 
In the present study, we demonstrated that compound 48 was a novel inducer of 
phosphorylation of the neurotrophic receptor TrkB and that compound 48 exhibited 
antidepressant effects in a mouse model of depression.  
The compound was selected through an in silico analysis that also identified two 
chemical agents that induce apoptosis in neuroblastoma cells (Nakamura et al, 2014). 
We report here on two compounds among the previously selected molecules that 
enhanced TrkB activity in a manner similar to the TrkB ligand BDNF. Compounds 48 
and 56 rescued cell survival in TrkB-expressing SH-SY5Y cells cultured with low FBS 
and activated the TrkB downstream signal cascade, including the AKT and ERK 
signaling pathways.  
BDNF and TrkB are widely expressed in various brain regions (Adachi, 2014; Autry 
and Monteggia, 2012). The BDNF-TrkB pathway is an attractive therapeutic target of 
depression (Li et al, 2008; Nestler and Carlezon 2006; Zhang et al, 2014; Cazorla et al, 
2011). To date, several TrkB agonists have been identified, including 
7,8-dihydroxyflavone (Jang et al, 2010b; Liu et al, 2010), deoxygedunin (Jang et al, 
2010a) and amitriptyline (Jang et al, 2009). Our present results demonstrated that 
compounds 48 and 56 were unique among previously reported TrkB ligands because 
these compounds strongly elicited TrkB phosphorylation in vivo despite their moderate 
effect in vitro. One reason for this apparent disparity in efficacy may be the different 
treatment times used for the in vitro and in vivo experiments. In the in vitro assays, we 
observed the elevation of TrkB phosphorylation within 60 min. In the in vivo study, we 
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examined TrkB phosphorylation 3 h after compound administration. Thus, the 
compounds might have been given adequate time to induce strong phosphorylation in 
vivo but not in vitro.  
We found that compounds 48 and 56 induced Tyr706 phosphorylation of TrkB, which 
is responsible for initiating TrkB autophosphorylation (Cunningham et al, 1997). 
Upregulation of downstream signals AKT and ERK and inhibition of TrkB 
phosphorylation by K252a are suggestive of the direct activation of TrkB by the 
compounds. Furthermore, because the compounds did not enhance cell proliferation in 
TrkA-expressing cells (Figure S3), the binding affinity of the compounds to TrkB might 
be stronger than that to TrkA, which has nerve growth factor as a natural ligand. 
However, it remains unclear whether the compounds specifically bind to the BDNF 
binding domain of TrkB. Further experiments will be required to elucidate the precise 
molecular mechanism of action for the compounds, including an analysis of surface 
plasmon resonance to determine their binding affinity to TrkB. Several studies have 
reported that drugs effective against depression require the expression and activation of 
brain TrkB to exert their antidepressant effect in mouse models (Hajszan et al, 2005; 
Monteggia et al, 2007). Interestingly, the intraperitoneal administration of compounds 
48 and 56 elicited a relatively higher level of TrkB phosphorylation in vivo than in vitro. 
In addition, a higher level of phosphorylation was also detected in the downstream 
factors AKT and ERK in the brain tissues of compound-treated mice. These data 
indicated the blood-brain permeability of these compounds, although the 
pharmacokinetics of the compounds has not yet been determined. The strong induction 
of TrkB signaling molecules in mouse brain tissue also indicated potential metabolic 
activation of the compounds before they were distributed to TrkB-expressing cells. 
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Further investigation will be necessary to determine the pharmacokinetics of the 
compounds in vitro and in vivo. Overall, compound 48 is a promising small molecule 
that may be developed as a novel drug against depression as well as for other 
BDNF-TrkB-associated neurodegenerative diseases, including Alzheimer and Parkinson 
diseases. 
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FIGURE LEGENDS 
 
Figure 1. Compounds 48 and 56 induce cell proliferation and activate TrkB 
signaling pathways in SH-SY5Y/TrkB and Neuro2a cells. 
(a) Growth curves for SH-SY5Y/TrkB cells treated with DMSO or increasing 
concentrations of BDNF or compound 48 or 56. SH-SY5Y/TrkB cells were cultured in 
2% FBS-containing medium for 9 days and treated as follows: “×”, DMSO; open circles, 
BDNF (1 ng/mL) or compound (0.06 µM); filled circles, BDNF (5 ng/mL) or 
compound (0.2 µM); open triangles, BDNF (10 ng/mL) or compound (0.6 µM); filled 
triangles BDNF (50 ng/mL) or compound (2 µM). Data represent mean ± S.E. **p 
<0.05, *p < 0.01 compared with DMSO. (b) Growth curves for Neuro2a cells treated 
with DMSO, or increasing concentrations of BDNF or compounds 48 or 56. Neuro2a 
cells were cultured in 2% FBS-containing medium for 9 days and treated as follows: 
“×”, DMSO; open circles, BDNF (1 ng/mL) or compound (0.1 µM); filled circles, 
BDNF (5 ng/mL) or compound (0.3 µM); open triangles, BDNF (10 ng/mL or 1 µM); 
filled triangles, BDNF (50 ng/mL) or compound (3 µM). Data represent mean ± S.E. (c) 
Time-course analysis for compounds 48 and 56 in SH-SY5Y/TrkB cells. The cells were 
treated with 0.3 µM of compounds 48 and 56 for the indicated times (5–60 min). DMSO 
was used as a negative control and BDNF was used as a positive control. The cell 
lysates were analyzed by immunoblotting using antibodies against TrkB and 
downstream molecules, as indicated. The results were quantified by chemiluminescence 
imaging, and the ratio of phospho-TrkB to total TrkB was calculated and is shown in the 
graph. (d) Concentration response of TrkB phosphorylation in SH-SY5Y/TrkB cells 
treated with compounds 48 and 56. The cells were treated with increasing 
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concentrations (0.03–1.0 µM) of compounds 48 and 56 for 30 min. (e) Western blot 
analysis for TrkB phosphorylation in Neuro2a cells treated with compound 48. The cells 
were treated with 0.1 or 1 µM of compound 48 for the indicated times (5–60 min). 
DMSO was used as a negative control, and BDNF was used as a positive control. 
 
Figure 2. Effects of compounds 48 and 56 depend on TrkB activation. 
(a) Immunoblot analysis of SH-SY5Y/TrkB cells pre-treated with the Trk inhibitor 
K252a followed by treatment with compounds 48 and 56. (b) Cell growth assay of 
SH-SY5Y/TrkB cells treated with 1 µM of compounds 48 and 56 in the presence or 
absence of K252a (100 nM). BDNF (5 ng/mL) was used as a positive control. Data 
represent mean ± S.E. **p < 0.05, *p < 0.01 compared with DMSO. (c) Morphological 
changes of SH-SY5Y/TrkB cells treated with 1 µM of compounds 48 and 56 in the 
presence or absence of K252a (100 nM). BDNF (5 ng/mL) was used as a positive 
control. Scale bar; 200 µm. 
 
Figure 3. Compounds 48 and 56 induce TrkB phosphorylation in cortex and 
hippocampus. 
(a) Male C57BL/6J mice (9 weeks old) were intraperitoneally administered 15 mg/kg of 
compound 48 or 56. DMSO and compound 37 were used as negative controls. Three 
hours after the injections, tissue lysates were prepared and analyzed by western blotting. 
(b) Immunohistochemical staining for phosphorylated TrkB in hippocampal tissues of 
C57BL/6J mice. Mice were intraperitoneal injected with 3 mg/kg of compound 48. 
DMSO and compound 37 were used as negative controls. (c) Quantification of 
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phospho-TrkB levels in hippocampus. The signal intensities from three mice were 
measured in nine fields at high magnification using WinROOF software. 
 
Figure 4. Effects of compound 48 on immobility time in the forced swim test (FST). 
(a) Male C57BL/6J mice were intraperitoneally administered 3 mg/kg/day of compound 
48 or DMSO for 21 days and subjected to the FST. The FST was performed for 10 min. 
The immobility time was recorded for 4 min after a pre-swim for 3 min. (b) Immobility 
time in the same FST as that for panel (a) was analyzed for 10 min. Data are indicated 
as mean ± S.E. of eight mice/group (p values are against the DMSO control group, 
one-way ANOVA followed by post hoc Dunnett’s test). (c) Body weight changes in 
C57BL/6J mice injected daily with 3 mg/kg of compound 48 for 21 days. Data are 
presented as mean ± S.E. 
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SUPPLEMENTARY INFORMATION 
 
SUPPLEMENTARY MATERIALS AND METHODS 
 
Reagents, cells, and mice 
Small molecules identified during in silico screening were purchased from Namiki Shoji 
Co. Ltd. (Tokyo, Japan). Details of the in silico screening are described in our previous 
study (Nakamura et al, 2014). All chemicals were dissolved in dimethyl sulfoxide 
(DMSO) (Nakalai, Kyoto, Japan) to a final concentration of 10 mM and kept at −20°C. 
Human neuroblastoma-derived SH-SY5Y/TrkB cells were a gift from Dr. Angelika 
Eggert (University Children’s Hospital Essen, Essen, Germany) and grown in RPMI 
1640 medium (Sigma, Tokyo, Japan) containing 10% heat-inactivated fetal bovine 
serum (FBS) (Gibco, CA, USA), 50 U/mL penicillin, 50 µg/mL streptomycin (Gibco), 
and 40 µg/mL G418 (Sigma). A mouse neuroblastoma cell line, Neuro2a, was 
maintained in Dulbecco’s modified Eagle’s medium (Sigma) supplemented with 10% 
FBS (Gibco), 50 U/mL penicillin, and 50 µg/mL streptomycin (Gibco). The cells were 
cultured at 37°C in the humidified atmosphere of a 5% CO2 incubator.  
 
In vitro compound screening  
SH-SY5Y/TrkB cells were seeded at a density of 1.0 × 104 cells/well in 24-well plates 
with medium containing 10% fetal bovine serum (FBS). After overnight culture, the 
cells were treated with dimethyl sulfoxide (DMSO) and 10 µM of the various 
compounds (#19, #30, #31, #36, #45, #48, #49, #50, #56, and #59). The plate was 
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incubated and monitored for 5 days. Images of the cells were captured and the cell 
number was counted on the fifth day after compound treatment. 
 
Cell growth/survival assay  
For the cell proliferation assay, SH-SY5Y/TrkB and Neuro2a cells were seeded at a 
density of 0.5 × 103 cells/well in 96-well plates with media containing 2% and 1% FBS, 
respectively. After overnight culture, the cells were treated with DMSO, the selected 
compounds (0.06–2.0 µM or 0.1–3.0 µM), or BDNF (1–50 ng/mL, Wako, Osaka, 
Japan), as indicated. The plate was incubated and monitored for 9 days in an IncuCyte 
live-cell imaging system (Essen Bioscience, Michigan, USA) according to the 
manufacture’s instructions. Images were captured in nine fields per well every 6 h to 
monitor cell confluency. SH-SY5Y/TrkB cells were pre-treated with the Trk receptor 
inhibitor K252a (Sigma) (200 nM) for 30 min after pre-culture in serum-free medium 
for 2.5 h to investigate whether the activities of compounds 48 and 56 were mediated 
through TrkB receptors. Cells were then treated with DMSO, BDNF (1 ng/mL), or 
compounds 48 or 56 (0.3 µM) for 1 h. The cells were collected, and the proteins were 
analyzed by immunoblotting. 
For the TrkB inhibition assay, SH-SY5Y/TrkB cells were seeded at a density of 0.5 × 
104 cells/well in 96-well plates with medium containing 2% FBS and allowed to attach 
overnight. Cells were then treated with BDNF (5 ng/mL) or compound (1 µM) in the 
presence of K252a (100 nM). The plate was incubated and monitored for 9 days using 
IncuCyte. Images were captured in nine fields per well every 6 h to monitor cell 
morphology.  
- 30 - 
SH-SY5Y/TrkA cells were seeded at a density of 0.5 × 103 cells/well in 96-well plates 
with medium containing 2% FBS. After overnight culture, the cells were treated with 
DMSO and increasing concentrations of the compounds (0.03–1.0 µM). The plate was 
incubated and monitored for 9 days in an IncuCyte live-cell imaging system (Essen 
Bioscience, Michigan, USA) according to the manufacture’s instructions. Images were 
captured in three fields per well every 6 h to monitor cell confluency.  
 
Immunoblotting 
The effects of the compounds in vitro were examined in cells plated in 6-cm diameter 
dishes and cultured for 2 days before the experiments. Cells were pre-cultured in 
serum-free medium for 2.5 h and then treated with DMSO, compounds, or BDNF for 
the indicated times. Cells were washed with cold phosphate-buffered saline (PBS), 
lysed on ice for 30 min in a CHAPS lysis buffer (50 mM Tris-HCl pH 7.5, 100 mM 
NaCl, 10 mM MgCl2, 1 mM EDTA, 10 mM CHAPS, a protease inhibitor cocktail and a 
phosphatase inhibitor cocktail [Roche]) and centrifuged at 4°C at 12100 g for 20 min. 
Protein concentrations were determined using a BCA protein assay kit (Pierce, 
Rockford, IL). The proteins were separated using SDS-PAGE and transferred onto 
Immobilon-P transfer membrane filters (Millipore). After being blocked with skim milk, 
the membranes were incubated with the following primary antibodies overnight at 4°C: 
anti-TrkB antibody (1:1 000 dilution; catalog #4603, Cell signaling, MA, USA), 
anti-TrkB antibody (1:1 000; #610101, BD Biosciences, CA, USA), anti-AKT antibody 
(1:1 000; #9272, Cell signaling), anti-ERK antibody (1:1 000, #9102S, Cell signaling), 
anti-β tubulin (1:10 000, MMS-435P, BioLegend, CA, USA), anti-phospho-TrkB (1:1 
000, #4621, Cell signaling), anti-phospho-AKT (1:1 000, #9271, Cell signaling), 
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anti-phospho-ERK (1:1 000, #9101, Cell signaling). Immunoreactive bands were 
visualized using SuperSignal West Pico Chemiluminescent Substrate (34080, Thermo 
Fisher Scientific, MA, USA) according to the manufacturer’s instructions.  
 
Compound administration in mice 
Eight-week-old male C57BL/6J mice (CREA Japan Inc., Tokyo, Japan) were 
maintained in a temperature-controlled environment for 1 week prior to the start of 
experiments. All animal experiments were performed in compliance with the 
regulations for animal experiments at the Chiba Cancer Center Research Institute after 
obtaining approval by the Animal Ethics Committee of Chiba Cancer Center. The mice 
were intraperitoneally administered DMSO or the compounds (3 mg/kg or 15 mg/kg 
body weight). After 3 h, the mice were killed, and cerebral cortical and hippocampal 
samples were collected. Tissue lysates were extracted from half of the collected tissues 
in homogenization buffer (20 mM Tris at pH 8.0, 137 mM NaCl, 1% Igepal, 10% 
glycerol) on ice and analyzed by immunoblotting with antibodies against phospho- 
(p)TrkB, TrkB, pAKT, AKT, pERK and ERK. The remaining half of the tissue was 
immediately fixed in 4% paraformaldehyde and embedded in OCT compound (Sakura, 
Tokyo, Japan). Frozen sections were cut using a cryostat, and the sections were 
subjected to immunohistochemistry assays using the anti-pTrkB antibody visualized 
with Alexa 488-conjugated secondary antibody (Thermo Fisher Scientific, Waltham, 
MA, USA). Images were captured using a confocal microscope (Leica), and the signal 
intensities were quantified in nine randomly selected fields on three slides using 
WinROOF software (version 7.0, Mitani Corp., Fukui, Japan). 
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Single compound administration test 
Male ICR mice (5 weeks old) were maintained in a temperature-controlled environment 
for 1 week before experiments. Animal experiments were performed in compliance with 
the regulations for animal experiments of the Chiba Cancer Center Research Institute 
after approval by the Animal Ethics Committee of the Chiba Cancer Center. Mice were 
orally administered a solution of 0.5% methylcellulose (Wako, Osaka, Japan) and 20, 
200, and 2000 mg/kg of compound 48 or intravenously injected with a solution of 10% 
DMSO (Wako, Osaka, Japan) and 0.75, 1.5 and 3 mg/kg of the compound. The body 
weights of mice were measured for 15 days after compound administration. 
Methylcellulose and DMSO were used as controls. 
 
Forced swim test 
Male C57BL/6J mice were intraperitoneal injected with DMSO or compounds (3 
mg/kg) for 21 days and then subjected to a forced swim test. The mice were allowed to 
adapt to the test room for 3 h after the injection. They were then placed in a clear glass 
cylinder with a diameter of 20 cm and height of 30 cm filled with clear water of 
approximately 25°C (a water depth of 20 cm did not allow the mice to touch the bottom 
of the cylinder). Their mobility was recorded for 10 min, and the time spent immobile 
was analyzed for the last 4 min of the test after a 3 min pre-swim as well as for the 
entire 10 min without a pre-swim. 
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SUPPLEMENTARY FIGURES 
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Supplementary Figure S2 
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 SUPPLEMENTARY FIGURE LEGENDS 
 
Supplementary Figure S1. Initial screening of compounds selected through in silico 
screening in TrkB-expressing SH-SY5Y cells. 
(a) Cell proliferation changes in SH-SY5Y/TrkB cells treated with 11 candidate 
compounds selected from previously screened compounds numbered 19 to 59. 
SH-SY5Y/TrkB cells were grown in normal culture medium containing 10% FBS for 9 
days. DMSO was used as a control. Images were captured 9 days after compound 
treatment. (b) Number of live SH-SY5Y/TrkB cells treated with the 11 compounds. 
SH-SY5Y/TrkB cells were treated with the 11 compounds, and the cell number was 
determined 5 days after a single treatment.  
 
Supplementary Figure S2. Chemical structures of two candidate molecules. 
(a) Structure and name of compound 48. (b) Structure and name of compound 56. 
 
Supplementary Figure S3. Compounds 48 and 56 do not affect cell proliferation in 
SH-SY5Y/TrkA cells. 
(a) Growth curves of SH-SY5Y/TrkA cells treated with compound 48. SH-SY5Y/TrkA 
cells were cultured in 2% FBS-containing medium for 9 days as follows: “×”, DMSO; 
open circles, compound (0.03 µM); filled circles, compound (0.1 µM); open triangles, 
compound (0.3 µM); filled triangles, compound (1 µM). Data represent mean ± S.E. 
**p <0.05, *p < 0.01 compared with DMSO. (b) Growth curves of SH-SY5Y/TrkA 
cells treated with compound 56. SH-SY5Y/TrkA cells were cultured in 2% 
FBS-containing medium for 9 days as follows: “×”, DMSO; open circles, compound 
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(0.03 µM); filled circles, compound (0.1 µM); open triangles, compound (0.3 µM); 
filled triangles, compound (1 µM). Data represent mean ± S.E. **p <0.05, *p < 0.01 
compared with DMSO.  
 
Supplementary Figure S4. TrkB phosphorylation in whole brain induced by 
compounds 48 and 56. 
Male C57BL/6J mice (9 weeks old) were intraperitoneally administered 3 mg/kg of 
compounds 48 and 56. DMSO was used as negative control. Three hours after injection, 
tissue lysates were prepared and analyzed by western blotting.  
 
Supplementary Figure S5. Changes in body weights of ICR mice in single-dose 
toxicity tests. 
Male ICR mice (5 weeks old) were divided into two groups. (a) Mice in one group were 
orally administered 20, 200, 2000 mg/kg of compound 48. A solution of 0.5% 
methylcellulose was used as a control. (b) Mice in the other group were intravenously 
injected with the compound. The body weights of the mice were measured for 15 days. 
Data represent mean ± S.D. **p < 0.05, *p < 0.01 compared with DMSO. 
 
- 40 - 
FUNDING AND DISCLOSURE 
 
This work was partly supported by MEXT KAKENHI Grant Number 25830092, 
24249061, and 24592703 and the Project for Development of Innovative Research on 
Cancer Therapeutics (P-Direct) from the Japan Agency for Medical Research and 
Development.  
- 41 - 
ACKNOWLEDGEMENTS 
 
The authors thank Dr. Angelika Eggert for giving SH-SY5Y/TrkA and SH-SY5Y/TrkB 
cells; Director Hiroki Nagase, Masatoshi Tagawa, Eiji Shimizu, Daisuke Matsuzawa, 
Haruna Tomizawa, Shingo Matsuda, Eriko Isogai, Yusuke Suenaga, Yasutoshi Tatsumi, 
Shunpei Sato, Islam Mohammad Sazzadul, Sheikh Afzal for advice and support on this 
study. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Neurochemistry International 
 
平成 28年 2月 投稿中 
